Tumor inhibition by genomically integrated inducible RNAi-cassettes by Kappel, Sven et al.
Tumor inhibition by genomically integrated
inducible RNAi-cassettes
Sven Kappel, Yves Matthess, Brigitte Zimmer, Manfred Kaufmann and Klaus Strebhardt*
Department of Gynecology and Obstetrics, School of Medicine, J.W. Goethe-University, Theodor-Stern-Kai 7,
D-60590 Frankfurt, Germany
Received July 21, 2006; Accepted August 10, 2006
ABSTRACT
RNA interference (RNAi) has emerged as a
powerful tool to induce loss-of-function phenotypes
by post-transcriptional silencing of gene expres-
sion. In this study we wondered whether inducible
RNAi-cassettes integrated into cellular DNA
possess the power to trigger neoplastic growth.
For this purpose inducible RNAi vectors containing
tetracycline (Tet)-responsive derivatives of the H1
promoter for the conditional expression of short
hairpin RNA (shRNA) were used to target human
polo-like kinase 1 (Plk1), which is overexpressed
in a broad spectrum of human tumors. In the
absence of doxycycline (Dox) HeLa clones express-
ing TetR, that carry the RNAi-cassette stably inte-
grated, exhibited no significant alteration in Plk1
expression levels. In contrast, exposure to Dox led
to marked downregulation of Plk1 mRNA to 3% and
Plk1 protein to 14% in cell culture compared to
mismatch shRNA/Plk1-expressing cells. As a result
of Plk1 depletion cell proliferation decreased to
17%. Furthermore, for harnessing RNAi for silen-
cing disease-related genes in vivo we transplanted
inducible RNAi-HeLa cells onto nude mice. After
administration of Dox knockdown of Plk1 expres-
sion was observed correlating to a significant
inhibition of tumor growth. Taken together, our
data revealed that genomically integrated RNAi-
elements are suitable to hamper tumor growth by
conditional expression of shRNA.
INTRODUCTION
RNA interference (RNAi) is a powerful tool for post-
transcriptional downregulation of endogenous genes. Small
double-stranded RNAs named short interfering RNAs
(siRNAs) or micro RNAs (miRNAs) depending on their
origin abrogate gene expression by sequence-speciﬁc binding
of cognitive mRNA. In the ﬁrst case binding of siRNA
evokes mRNA elimination by RNAi whereas binding of
miRNA results in mRNA translation arrest (1,2). For transient
gene silencing numerous investigators administered synthetic
small double-stranded siRNAs with 2 nt 30-overhangs to
mammalian cells (3,4). Alternative attempts for prolonged
RNAi-based gene silencing have been made through applica-
tion of Pol III (RNA polymerase III)-promoter driven expres-
sion of short hairpin RNAs (shRNAs) that are subsequently
processed to siRNAs (5–8). In this regard most commonly
used Pol III-dependent transcriptional units are the promoters
for U6 snRNA and for H1 RNA. The use of Pol III promoters
offers two important advantages: (i) a high transcription
rate of  1–4 · 10
5 transcripts per cell, (ii) no additional
nucleotides are added to the transcript allowing for optimal
functional activity of shRNAs. The structures of Pol III pro-
moters fall into three classes. One of these, representing type
III genes, encompasses the H1 promoter which consists of
four cis-acting elements lying in the 50-ﬂanking sequence
very closely together in a region of 100 bp in length: the
TATA box (positions  26 to  31 relative to the transcription
start site), the PSE (proximal sequence element; positions
 51 to  68) and the DSE (distal sequence element; positions
 69 to  100) containing a staf binding site and an octamer
motif (5,9). Although the U6 snRNA promoter, which
belongs also to type III of the Pol III promoter family,
exhibits a distance of  150 bp between PSE and DSE, the
regulatory units (PSE and staf binding site of DSE) are adja-
cent in the H1 promoter. Both, staf binding site and octamer
motif, as components of the DSE, contribute to full promoter
activity. Additionally, PSE- and DSE-binding factors seem
to interact (10–12).
A major obstacle for the generation of loss-of-function
mutants is the constitutive expression of shRNA when tar-
geted genes are essential for cell survival. Consequently
many attempts were made to develop inducible promoters
for the expression of shRNA dependent on inducers like tetra-
cycline (13,14), steroid hormones (15), heat shock proteins
(16) or using the Cre-LoxP system (17). Restrictions in ver-
satility of these promoters are caused by their leakiness in the
uninduced state and are partially due to pleiotropic effects
which occur by inducing mechanisms themselves.
We identiﬁed and cloned the human serine/threonine
kinase polo-like kinase 1 (Plk1) and demonstrated its
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evolutionally highly conserved and plays a leading role for
numerous aspects of mitotic progression including
G2/M-transition (19), centrosome maturation (20,21), mitotic
spindle formation (22) and activation of the anaphase-
promoting complex (23,24). Plk1 is activated by phosphory-
lation at the G2/M-phase boundary. In vivo phosphorylation
of Plk1 at Ser-137 and Thr-210, which is located in the
activation loop of the kinase domain, occurs in mitosis
(25). Levels of Plk1 mRNA and protein are massively
elevated in many kinds of tumors like breast, ovarian, non-
small cell lung cancer and melanomas (18,26–29). High
Plk1 expression often correlates to poor prognosis of cancer
patients (29,30) Additionally, overexpression of Plk1 induces
transformation in NIH/3T3 ﬁbroblasts and tumor progression
in nude mice (31). Interestingly, inhibition of Plk1 expression
in cancer cells via application of antisense oligonucleotides,
siRNA or vector-mediated expression of shRNA resulted in
mitotic arrest and induction of apoptosis in vitro and
in vivo (4,32,33). Increasing evidence suggests that Plk1
represents an ideal target for cancer drug development (34).
In this study we investigated whether inducible RNAi
cassettes expressing shRNA against Plk1 integrated into the
genome are suitable genetic elements to protect mammalian
cells against neoplastic proliferation. For this purpose we
used Tet-inducible derivatives of the H1 promoter driving
the expression of shRNA targeting the mRNA of Plk1.
Following genomic integration we studied the tetracycline-
dependent kinetics of activity of different inducible promoter
variants reﬂected by the conditional downregulation of Plk1
in HeLa cells. Analysis of quantitative properties such as
leakiness under non-induced conditions and full activity in
the on-state supported the functional evaluation of the novel
regulatory systems. In addition, the conditional knockdown
of Plk1 in cultured cells and in xenografted tumor
mouse models helped to answer the question whether the
genomic integration of inducible shRNA/Plk1 cassettes
bears the potential to counteract tumor cell proliferation in
a conditional manner.
MATERIALS AND METHODS
Genetic constructs for the expression of shRNAs
targeting Plk1
Three types of expression plasmids (i) ptet O-T-hH1/
shRNAPlk1 (pUS); (ii) ptet T-O-hH1/shRNAPlk1 (pDS)
and (iii) ptet O-T-O-hH1/shRNAPlk1 (pUS/DS) containing
different variants of Tetracycline-inducible H1 promoters
encoding shRNA targeting Plk1 were generated as described
previously (14). The targeting sequence in human Plk1 (Gen-
Bank accession no. NM_005030) is GTGCTTCGAGATCT-
CGGAC corresponding to the coding region 198–216 relative
to the ﬁrst nucleotide of the start codon. The plasmid phH1/
shRNAPlk1MM (pwtH1MM) containing the wild-type H1
promoter expressing a mismatched shRNA (50-GUGCA-
CUGAGAUCUCGGACUU) was used for the generation of
stable clones as constitutive control. Furthermore, the plas-
mids pUS, pDS and pUS/DS expressing also the mismatched
shRNA (GUGCACUGAGAUCUCGGACUU) were used for
the generation of stable clones as inducible control.
Generation of stable cell clones
T-REx -HeLa cells stably expressing bacterial TetR were
obtained from Invitrogen GmbH (Karlsruhe, Germany) and
cultured in MEM with Earle’s and GlutaMAX  (Invitrogen
GmbH) containing 10% Tet system approved fetal calf serum
(PAA Laboratories GmbH, Pasching, Austria), penicillin-
streptomycin (Invitrogen GmbH) and 5 mg/ml blasticidin
(Invitrogen GmbH).
T-REx -HeLa cells were transfected with the above listed
RNAi-plasmids pUS, pDS, pUS/DS for stable integration and
subsequent inducible expression of shRNA/Plk1 or shRNA/
Plk1MM using Fugene 6 (Roche Diagnostics, Mannheim,
Germany) as transfection reagent according to the manufac-
turer’s instructions. In addition, pwtH1MM was transfected
under the same conditions. Transfected cells were selected
by using culture medium containing 1.5 mg/ml geneticin
(G418; Invitrogen GmbH) starting 24 h after transfection.
Altogether selection of resistant cells lasted for a period of
25 days. Subsequently geneticin-resistant cells were trypsi-
nized, centrifuged and resuspended in culture medium. Cell
numbers were determined using a hemacytometer. Selected
cells were diluted to obtain 1 cell/200 ml, plated out onto
96-well plates and cultivated without antibiotic until a cell
number of 5 · 10
5 was reached. Cell clones were expanded
under continuous selection using 500 mg/ml geneticin
(G418; Invitrogen GmbH).
PCR, Southern blot analysis and preparation of
genomic DNA
To test whether resistant clones contain integrated plasmid
DNA including different promoter variants including the
shRNA-coding region, genomic DNA was prepared using a
DNA Blood Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. To gain ﬁrst evidence for
complete integration of inducible RNAi-cassettes (complete
promoter including shRNA-coding sequence), we performed
PCR-based controls. As sense primer we used 50-CGCCCTG-
CAATATTTGCATG-30 binding the H1 promoter variants at
a5 0 position. As antisense-primer we used 50-CCGTCGACT-
GCAGAATTCGAAGC-30 which binds to a plasmid-derived
sequence 30 of shRNA-coding stretch. Genomic DNA from
non-transfected HeLa cells (negative) and plasmid DNA
(positive) were used as controls.
To examine the copy number of promoter cassettes inte-
grated into the genome of different cell clones, a Southern
blot analysis using genomic DNA digested with HindIII
was performed as described previously (35). Integrated
RNAi-cassettes were detected with an [a-
32P]-labeled
probe generated using the following reaction mixture: 100–
200 mCi of [a-
32P]dCTP (6000 Ci/mmol), the three other
dNTPs (each at 50 mM) and 200 nM of the primers 50-GCGG-
ACAGGTATCCGGTAAG-30 (sense) and 50-CCGTCGACT-
GCAGAATTCGAAGC-30 (antisense).
Cell culture and induction of shRNA expression
following addition of doxycycline
Positive cell clones with stably integrated, inducible RNAi-
cassettes were cultured as described above. During the
analysis of shRNA-based gene silencing culture medium
contained geneticin (G418; Invitrogen) at a concentration of
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was induced through the addition of Dox (doxycycline
hydrochloride; Sigma, Taufkirchen, Germany) at different
concentrations (1–10 mg/ml) beginning simultaneously with
cell seeding. Dox-containing medium was replaced every
24 h. Each experiment was performed at least ﬁve times.
Cell lysis and Western blot analysis
At 120 h after induction with Dox, cell extracts and Western
blots were prepared as described previously (4,36). Mem-
branes were incubated with monoclonal antibodies against
Plk1 (1:300; Biomol, Hamburg, Germany), polyclonal anti-
bodies against b-actin (1:200000; Sigma) and with goat
anti-mouse serum (1:2000; Santa Cruz Biotechnology Inc.,
Heidelberg, Germany). Immunocomplexes were visualized
as described previously (4).
Preparation of RNA and Northern blot analysis
Total RNA was isolated using RNeasy Mini Kit according to
the manufacturer’s protocol (Qiagen), 120 h after induction
with Dox. Probes for Northern blots were generated by radio-
labeling antisense strands of Plk1 as described previously (4).
Northern blotting, hybridization and standardization were
carried out as described previously (35).
Determination of cell proliferation
The growth rate of 1.5 · 10
5 cells was determined by count-
ing cells using a hemacytometer at 24, 48, 72, 96 and 120 h
after beginning of induction. Wild-type HeLa cells were trea-
ted with 5 mg/ml Dox to test its effect on cell proliferation.
Xenografted tumor mouse model
Each ﬂank of 8-week-old male athymic mice (Harlan-
Winkelmann, Borchen, Germany) was inoculated with 1 ·
10
7 stably transfected T-Rex-HeLa cells resuspended in
0.5 ml sterile saline solution subcutaneously. HeLa clones
for inducible expression of shRNA/Plk1MM were inoculated
on the left ﬂank whereas clones for inducible expression of
shRNA/Plk1 were inoculated on the right ﬂank. Mice were
distributed randomly into two groups (12 animals each) for
the subsequent analysis of tumor development with and
without Dox-treatment. Dox (Sigma) was applied as 0.2%
solution via the drinking water with additional 3% sucrose
dissolved in natural mineral water starting 2 days after inocu-
lation. Drinking water for control mice contained 3% sucrose
without Dox. Xenografted tumors were measured in two
right-angled dimensions by a sliding caliper twice a week.
Absolute tumor volumes were evaluated according to V
(mm
3) ¼ p/6 ab
2 with a > b. Relative tumor volumes repre-
sent the ratio of current tumor volume and corresponding
volume at the beginning of the study. After inoculation mea-
surements started at day 23 and ﬁnished at day 51 followed
immediately by sacriﬁcing the animals. Eight individual
tumors from the Dox-treated as well as from the untreated
groups were analyzed. Tumor mRNA was prepared as
described previously (35).
Statistical methods
All experiments were performed at least in triplicate.
Standardization and statistics were performed as described
previously (4). Paired T-tests (two-sided) were performed
for all experiments. Signiﬁcant reductions (P < 0.05) were
indicated with an asterisk.
RESULTS
Generation of HeLa cell lines carrying
RNAi-cassettes for the conditional expression
of shRNA targeted to Plk1
Different H1 promoter variants were used for the generation
of stable cell lines carrying inducible RNAi-cassettes as
integral component of chromosomal DNA. A palindromic
operator sequence from the tet operon control region, called
TetO (37) for the occupation by the TetR was inserted
adjacent to the TATA box (Figure 1A): (i) In the US-type
promoter the TetO was inserted upstream of the TATA box
and substituted completely the sequence connecting PSE
element and TATA box; (ii) in the DS-type the TetO was
inserted downstream of the TATA box and partially replaced
the sequence between TATA box and the initiation site for
transcription of the H1 RNA; (iii) the US/DS-type contains
two TetO elements located 50 and 30 connected to the
TATA box (14). In all constructs the distance found in the
wild-type H1 promoter between the PSE and transcription
start site was kept constant. To examine the response of
different H1 promoter constructs, as elements integrated
into the genome of HeLa cells, to an effector, we studied
the inhibition of Plk1 expression by conditional expression
of shRNA/Plk1 driven by these promoters. For this purpose
we generated RNAi-cassettes and linked all H1 promoter
constructs to a 19 bp Plk1-derived sequence that, when
transcribed, forms a shRNA containing a 19 bp stem and a
9 bp loop which is likely processed to siRNA. A termination
sequence was included which consists of ﬁve thymidine
nucleotides. Two uracil nucleotides are predicted to consti-
tute the 30 end of the corresponding shRNA. Vectors for
the expression of Plk1-speciﬁc shRNA or a corresponding
mismatched sequence used for the integration as stable
RNAi-cassettes were named according to the location of
TetO sequence(s): pUS (upstream), pDS (downstream) and
pUS/DS (upstream/downstream). In addition, a construct
was generated containing the wild-type H1 promoter consti-
tutively driving the expression of a mismatched Plk1
sequence (phH1/shRNAPlk1MM) as control.
T-REx -HeLa cells stably expressing bacterial TetR were
transfected with plasmids containing different Tet-responsive
RNAi-cassettes or a plasmid containing the wild-type H1 pro-
moter constitutively expressing the mismatched sequence
(Figure 1).
After clonal selection cells were analyzed for the genomic
integration of the above described RNAi-cassettes. A PCR-
based analysis disclosed the existence of the above described
H1 promoter elements driving the expression of shRNA/Plk1
or shRNA/Plk1MM in the genomes of transfected cells
(Figure 2A). Subsequent sequencing of the PCR products
conﬁrmed the integrity of the promoter constructs encom-
passing corresponding shRNA-sequences. Furthermore we
investigated the number of integrated copies of elements. A
Southern blot analysis revealed two integration sites for the
US clone (Figure 2B, lane 2) whereas the DS and US/DS
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lanes 3 and 4).
Dox-dependent reduction of cellular Plk1 expression
using different Tet-responsive H1 promoter variants
We investigated the dose-response for Dox, a tetracycline
derivative, which was shown previously to be a very efﬁcient
effector for TetR (38). In the absence of the synthetic regu-
lator Dox TetR binds to its operator and prevents expression
of the shRNA transcripts by RNA polymerase III (Figure 1B).
To evaluate the response of different promoter constructs to
Dox, at ﬁrst Plk1 mRNA levels of different cell clones
(US, DS and US/DS) were analyzed by Northern blotting.
We chose elevated concentrations of Dox ranging from 1 to
10 mg/ml for efﬁcient induction of gene expression, because
TetR is highly expressed under the control of a constitutive
CMV promoter. Plk1 mRNA was reduced to levels of 3%
(P < 1 · 10
 4) by shRNA/Plk1 driven by the US clone, to
levels of 3% (P ¼ 3 · 10
 4) by the DS clone and to levels
of 9% (P ¼ 0.002) by the US/DS clone compared to the
Plk1 mRNA level in the clone constitutively expressing the
mismatched sequence (Figure 3A, lanes 1, 5, 9 and 13),
120 h after induction with 10 mg/ml Dox. To investigate
whether the reduction of Plk1 mRNA levels is speciﬁc and
correlates to the sequence of the Plk1 shRNA, we generated
clones which express a mismatched sequence under the con-
trol of all three promoter types. All clones were tested for the
presence of the correct promoter and shRNA-coding
sequences. We repeated the expression analysis under the
same conditions as described above. A signiﬁcant alteration
of the endogenous Plk1 level was not observed using a mis-
matched shRNA sequence driven by the US, DS or US/DS
promoter (Figure 3A, lanes 14–22). Thus, downregulation
of the endogenous Plk1 transcript levels seems to be due to
an RNAi-mediated mechanism targeting the Plk1 transcript.
Although in the absence of Dox the US and US/DS promoters
showed no leakiness, the mRNA level of Plk1 was reduced to
levels to 65% by the DS promoter in the off-state (Figure 3A,
lanes 2, 6 and 10).
Just like all three cell clones containing different promoter
types driving the expression of shRNA targeting Plk1 showed
a signiﬁcant downregulation of Plk1 mRNA in response
to increasing concentrations of Dox, we wondered whether
silencing of endogenous transcription via expression of
shRNA/Plk1 also translates to altered Plk1 protein
levels. The US clone exhibited a low level of Plk1 protein
which was signiﬁcantly reduced to 14% (P < 1 · 10
 4)
(Figure 3B, lane 5) compared to the clone constitutively
driving the expression of shRNA/Plk1MM (MM clone)
(Figure 3B, lane 1), 120 h after induction with Dox at a
concentration of 10 mg/ml. The MM clone showed an
Figure 1. Genomically integrated cassettes for constitutive or Tet-inducible expression of shRNA/Plk1 or shRNA/Plk1MM. (A) Different promoter derivatives
for constitutive or Tet-inducible expression of shRNA/Plk1 or shRNA/Plk1MM were stably integrated into TetR-expressing HeLa cells followed by isolation of
single cell clones: wild-type H1 promoter for constitutive expression of mismatch shRNA, US-type promoter containing TetO upstream of the TATA box; DS-
type promoter containing TetO downstream of the TATA box and the US/DS-type promoter containing TetO upstream and TetO downstream of the TATA box.
TetO, tetracycline operon; TATA, TATA box. (B) Schematic representation of promoter function in absence ( Dox) and presence of doxycycline (+Dox).
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(data not shown) suggesting the speciﬁcity of our RNAi-
based approach. In the absence of Dox the US clone exhibited
a Plk1 protein level of 92% compared to the level of
HeLa cells expressing the mismatch shRNA (MM) under
the control of the parental H1 promoter (Figure 3B, lanes 1
and 2). The expression of mismatched shRNA under the
control of all three inducible promoters did not inﬂuence
endogenous Plk1 protein levels signiﬁcantly either
(Figure 3B, lanes 14–22). The analysis indicates a very
broad range of Plk1 regulation for the US clone under
different Dox conditions.
At a concentration of 10 mg/ml the US/DS clone showed
nearly similar properties compared with the US clone;
although in the non-induced state Plk1 protein levels
were found to be 95% compared to control cells
(Figure 3B, lane 10), a signiﬁcant downregulation in the
induced state was observed (15% Plk1 protein, P ¼ 1 ·
10
 4) (Figure 3B, lane 13). At a concentration of 1 mg/ml
Dox the US and the US/DS clone responded differently;
whereas US/DS clone exhibited no signiﬁcant downregula-
tion of the Plk1 protein compared to the non-induced state
(90%, P > 0.5) (Figure 3B, lane 11), pUS clone differed
clearly by showing a signiﬁcantly reduced Plk1 protein
level (67%, P < 0.05) (Figure 3B, lane 3).
The DS clone also showed a signiﬁcant downregulation of
Plk1 protein in the presence of 10 mg/ml Dox (15%, P ¼ 1 ·
10
 4) (Figure 3B, lane 9). A limited extent of leakiness could
be observed in the non-induced state (81% Plk1 protein)
(Figure 3B, lane 6). Thus, by using the US clone or the
US/DS clone for the expression of shRNA/Plk1, transcript
and protein levels of Plk1 could be triggered in a wider
range as seen for the DS clone.
Doxycycline-triggered downregulation of Plk1 leads to
the inhibition of cancer cell proliferation
Numerous studies demonstrated the limited duration of gene
silencing activity by the application of siRNA or by transient
transfection of shRNA-expressing vectors. This is a major
disadvantage of exogenously administered RNAi-inducing
agents. Because of this reason these techniques led only to
a transient inhibition of cancer cell proliferation through
silencing of Plk1 (4,14,33,35,39). To prolong the RNAi-
based effects on Plk1-function, RNAi-cassettes were inte-
grated into the genome of TetR-expressing HeLa cells and
tested for their capability to trigger cancer cell proliferation.
For this purpose all four established cell clones were
cultivated with or without Dox.
US cells showed the highest proliferation rate of 78%
compared to wild-type HeLa cells under non-induced condi-
tions, 120 h after seeding (Figure 4A). Cells derived from the
DS clone or from the US/DS clone exhibited in the absence
of Dox reduced proliferative activity of 54 and 68%, respec-
tively, compared to wild-type HeLa cells (Figure 4B and C).
In contrast, after addition of 5 mg/ml Dox cell proliferation of
all three clones was signiﬁcantly inhibited compared to the
non-induced state: US clone to 33% (P ¼ 3 · 10
 4), DS
clone to 20% (P ¼ 6 · 10
 4) and the US/DS clone to 17%
(P ¼ 2 · 10
 4) (Figure 4A–C). To evaluate whether the effect
of proliferative inhibition is inﬂuenced by the addition of Dox
alone, wild-type HeLa cells were cultivated at a Dox concen-
tration of 5 mg/ml for 120 h. Wild-type HeLa cells showed no
signiﬁcant alteration in proliferative activity compared to
HeLa cells grown in the presence of Dox (P > 0.5)
(Figure 4A–C). Mismatched shRNA expression driven by
all three promoter types did not alter cell proliferation with
or without Dox signiﬁcantly compared to the growth rate of
control cells (Figure 4A–C).
Conditional RNAi-mediated silencing of Plk1 reduces
tumor growth in xenografted mice
Tetracycline-inducible expression systems have been
widely used in mouse models for studying gene function
(40). To test whether inducible gene silencing driven by
Figure 2. Detection of genomically integrated RNAi-cassettes in HeLa cell
clones. Genomic DNA from HeLa cell clones digested with HindIII was
further analyzed. (A) PCR was performed to amplify a sequence of 185 bp in
length enclosing different H1 promoter derivatives and shRNA-coding
regions. Subsequent sequencing of amplified fragments revealed the
authentical integration of different RNAi-cassettes. DNA from wild-type
HeLa cells was used as negative control (lane 7), recombinant plasmid DNA
was used as positive control (lane 6). (B) Southern blot analysis was
performed to determine the number of integrated RNAi-cassettes (arrows). A
radioactive probe specific for RNAi-cassettes was used.
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culture possesses the power to inhibit neoplastic growth in
xenograft models, we inoculated 8-week-old immuno-
deﬁcient athymic nude mice with different cell clones
containing the US and the US mismatched RNAi-cassettes.
The injection of the US clone on one ﬂank and the corre-
sponding US mismatched clone on the other ﬂank provided
a side-by-side comparison in the presence or absence of
Dox. Cells (1 · 10
7) were injected subcutanously into each
ﬂank of nude mice. The relative tumor growth of xenografted
conditional RNAi-tumors analyzed for 28 days terminating
51 days post inoculation is depicted in Figure 5A. Mice
inoculated with different US cell clones showed a down-
regulation of tumor growth after induction. If 0.2% Dox
was added to the drinking water of tumor-bearing mice,
US clone-derived tumors exhibited a signiﬁcant reduction
to 47% (P ¼ 0.006) 51 days after inoculation compared to
the corresponding mismatched shRNA-expressing clone
(Figure 5A). The growth behavior of the non-induced US
clone, the induced and non-induced US mismatch clone did
not differ signiﬁcantly (P > 0.5) (Figure 5A).
In order to examine whether reduced tumor growth corre-
lates with silencing of Plk1 expression, total mRNA from US
tumors and US mismatched tumors derived from mice treated
with or without Dox were subjected to a Northern blot anal-
ysis. Consistent with the ﬁndings of reduced US tumor
growth for mice treated with Dox, the average Plk1 mRNA
levels of respective mice were reduced to 73% (P ¼ 0.034)
(Figure 5B) compared to control mice that express
mismatched shRNA with Dox-treatment (Figure 5B).
DISCUSSION
In our study expression of shRNA was driven by a condi-
tional tetracycline-dependent H1 promoter integrated into
the genome of TetR- expressing HeLa cells. This system
was used to downregulate the expression of endogenous
Plk1 aiming at the inhibition of cancer cell proliferation
in vitro and in a xenograft mouse model. Although shRNA/
Plk1 under the control of different H1 promoter variants in
the absence of Dox inﬂuenced the expression of Plk1 only
Figure 3. Knockdown of Plk1 mRNA and protein by Tet-inducible expression of shRNA/Plk1 using different promoter types stably integrated into the genome of
HeLa cell clones. (A) Northern blot analysis of Plk1 mRNA. HeLa cell clones containing a wild-type H1 promoter constitutively expressing shRNA coding for a
mismatch sequence (MM) was used as control (lane 1); Plk1 mRNA expression in Tet-inducible US-type promoter-derived cell clones driving the expression of
shRNA/Plk1 (lanes 2–5); Plk1 mRNA expression in Tet-inducible DS-type promoter-derived cell clones driving the expression of shRNA/Plk1 (lanes 6–9); Plk1
mRNA expression in Tet-inducible US/DS-type promoter-derived cell clones driving the expression of shRNA/Plk1 (lanes 10–13). Plk1 mRNA expressioni n
Tet-inducible US-, DS- and US/DS-type promoter-derived cell clones driving the expression of shRNA/Plk1MM (14–22). Administration of different Dox
concentrations lasted for 120 h. For standardization ethidiumbromide staining of 28S rRNA was chosen. Plk1 mRNA levels were presented as percentage of Plk1
mRNA levels in cell clones constitutively expressing mismatched shRNA. (B) Immunoblot analysis of Plk1 protein expression. Same distribution of samples as
shown in (A). For standardization b-actin expression was used. Plk1 protein levels were presented as percentage of Plk1 protein levels in cell clones
constitutively expressing mismatched shRNA. Significant reductions (P < 0.05) are indicated with an asterisk.
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tion of shRNA/Plk1 expression 120 h post administration of
Dox led to signiﬁcantly decreased mRNA and protein levels.
These effects result in a distinct inhibition of cancer cell pro-
liferation in vitro and in vivo.
A Pol III-based promoter using the prokaryotic TetR-TetO
system has been used originally to control the expression of
eukaryotic tRNA in Saccharomyces cerevisiae (41). In recent
years many approaches tested the TetO-TetR system for con-
ditional expression of different RNAs in mammalian cells
(42–44). In this context especially the U6 promoter (42)
and the H1 promoter (14) were analyzed structurally and
functionally in detail. Still, the use of the U6 promoter impli-
cates some disadvantages: the cellular response to the intro-
duction of increased active U6 promoter is not an increase
of endogenous transcriptional activity but rather an increase
of U6 transcript degradation (45). This response describes a
so far unrecognized U6-speciﬁc intracellular negative feed-
back mechanism through which accumulation of U6
snRNA is counteracted. Owing to this observation which is
a major obstacle to guarantee high expression rates, we
decided to investigate the properties of different inducible
H1 promoter variants. We studied the functional conse-
quences of varying TetO localizations upstream of the tran-
scription start site within the H1 promoter for the
conditional expression of shRNA/Plk1 as element integrated
into the genome of HeLa cells. Different positioning of the
TetO sequence showed considerable differences for the activ-
ity of the H1 promoter variants in the presence or absence of
Dox; whereas stably integrated into the genome both, US-
type and US/DS-type, promoters exhibited low leakiness
(93–104% Plk1 mRNA; 92–95% Plk1 protein), the DS-type
promoter showed higher basal activity in the non-induced
state as reﬂected by lower cellular Plk1 mRNA (65%) and
protein levels (81%). Application of Dox resulted in a strong
reduction of Plk1 mRNA (3–9%) and protein levels (14–
15%) independent of the promoter derivative used. The low
leakiness of the US promoter might be due to the binding
of the Tet repressor to a location upstream of the TATA
box which plays a major role for the transcriptional activity
of the H1 promoter (9). In contrast, alterations of the
sequence downstream of the TATA box as shown by Myslin-
ski et al. (9) or binding of the Tet repressor to this region does
not seem to have a major inhibitory effect on the transcrip-
tional activity of the H1 promoter.
A difference to previous transient transfection experiments
was found for the non-induced state: the leakiness of the DS-
and US/DS-type promoter was less pronounced in the stable
situation compared to the transient state (14). This quantita-
tive difference of the transcriptional readout might be due
Figure 4. Proliferative activity of inducible cell clones expressing shRNA/
Plk1MM or shRNA/Plk1. HeLa cell clones containing stably integrated H1
promoter derivatives were induced for the expression of shRNA/Plk1MM or
shRNA/Plk1MM by addition of 5 mg/ml Dox to the culture medium. (A)
Proliferative activity of cell clones containing promoter of the US-type for the
expression of shRNA/Plk1MM or shRNA/Plk1; (B) proliferative activity of
cell clones containing promoter of the DS-type for the expression of shRNA/
Plk1MM or shRNA/Plk1; (C) proliferative activity of cell clones containing
promoter of the US/DS-type for the expression of shRNA/Plk1MM or
shRNA/Plk1. Values are shown in percent compared to wild-type HeLa cells.
Significant growth inhibitions (P < 0.05) are indicated with an asterisk.
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situation compared to only one or two copies of the
RNAi-cassette per genome found in this study. Single
RNAi-cassettes seem to be sufﬁcient to knockdown endo-
genous Plk1 mRNA to levels of 3–9% at a concentration of
10 mg/ml Dox. In contrast, a multitude of copies in the tran-
sient situation (14) does not seem to augment the silencing
effect compared to the impact of two integrated copies
analyzed in this study under induced conditions but rather
seem to enhance unwanted leakiness in the non-induced state.
In addition to the functional characterization of genomi-
cally integrated RNAi-cassettes targeting the human Plk1
gene in cell culture, we wondered whether this approach is
suited for efﬁcient gene silencing in vivo using a xenograft
mouse model. Hitherto in only a few studies conditional
tetracycline-dependent RNAi-systems were applied: (i)
Although the conditional knockdown of the PI 3-kinase in
an orthotopic prostate cancer mouse model failed to inhibit
tumor growth in nude mice, it reduced invasive tumor cell
growth (formation of metastasis) (46). (ii) The candidate
tumor suppressor KILLER/DR5 is a DNA damage-inducible
p53-regulated death receptor for the tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), which is a prom-
ising agent for cancer therapy. However, its contribution to
the inhibition of tumor growth and its role as a determinant
of chemosensitivity are poorly understood. Inducible silenc-
ing of KILLER/DR5 in vivo by exposure of mice to Dox
led to accelerated growth of bioluminescent tumor xenografts
and conferred resistance to the chemotherapeutic agent 5-
ﬂuorouracil (47). Recently, shRNA-based gene silencing of
hypoxia-inducible factor-1a, oncogenic BRAF or the Met
receptor was tested in different xenograft models using
nude mice (48–50). These studies demonstrated that inducible
RNAi is a versatile tool to validate tumor targets in vivo. Our
study shows a downregulation of tumor growth by condi-
tional Dox-dependent expression of shRNA/Plk1 driven by
genomically integrated RNAi-elements. Still, knockdown of
Plk1 in murine tumors was not as efﬁcient as in cell culture
where a selective pressure by G418 was maintained during
the entire experiment. We cannot exclude that cell clones
transplanted onto nude mice lost partially RNAi-cassettes
during the long period of tumorigenesis which took 51
days. To enhance the observed inhibitory effect, in future
experiments clones harboring additional copies of the
inducible RNAi-cassette could be used for prolonged and
more intense Plk1 silencing.
Plk1 is a key element of mitotic progression. Plk1 is
overexpressed and has prognostic potential in cancer.
Accumulating evidence highlights its potential as therapeutic
target (34). Multiple studies analyzed the downregulation of
Plk1 by antibodies, dominant-negative forms, antisense
oligonucleotides, chemically synthesized siRNA and vector-
driven expression of shRNAs (4,20,32,35,51). Since the
downregulation of Plk1 in all previous experiments was tran-
sient, several important issues could not be addressed:
(i) Depending on the dose and duration of Plk1 silencing, it
is important to monitor the effects in cancer and normal
cells; (ii) Mechanisms involved in cell signaling leading to
apoptosis by Plk1-inhibitors are still unknown; (iii) How
does the mitotic delay caused by Plk1 silencing correlate
with the apoptotic response? These questions can hardly be
answered under transient conditions, which often include
unwanted side-effects caused by transfection-based distur-
bances of the analyzed cells. Taken together, a stable cell
system that allows the regulation of Plk1 activity could be
a versatile tool to deﬁne its role during the cell cycle more
precisely. Furthermore, experience with the long-term
RNAi-based modulation of gene expression is limited.
Thus, in addition to a better understanding of the mitotic
Figure 5. Tumor growth in nude mice after Dox-induced expression of
shRNA/Plk1MM or shRNA/Plk1. Mice were inoculated with 1 · 10
7 HeLa
cell clones in each flank HeLa clones for inducible expression of shRNA/
Plk1MM were inoculated on the left flank whereas clones for inducible
expression of shRNA/Plk1 were inoculated on the right flank. (A) Relative
tumor volumes of xenografted US-type HeLa tumors for inducible expression
of shRNA/Plk1MM or shRNA/Plk1 either after induction with Dox or in the
absence of Dox starting 23 days after inoculation. Significant inhibition of
tumor growth (P < 0.05) is indicated with an asterisk. (B) Northern blot
analysis of Plk1 mRNA under the influence of shRNA/Plk1MM or shRNA/
Plk1 expression. Plk1 mRNA expression in US-type promoter-derived HeLa
tumors of mice without Dox-treatment (lanes 1 and 3) in comparison to
tumors of mice treated with Dox (lanes 2 and 4). For standardization
ethidiumbromide staining of 28S rRNA was chosen. Significant reduction
(P < 0.05) is indicated with an asterisk.
4534 Nucleic Acids Research, 2006, Vol. 34, No. 16regulation using our cell system we expect to learn more
about the cellular response to prolonged RNAi-based gene
silencing, which is an important issue for RNAi-based
inhibitors on their way to clinical applications. In summary,
our data indicate that inducible tetracycline-dependent
expression of shRNA targeting molecules essential for cell
survival can be used for the generation of loss-of-function
phenotypes in vitro and in vivo. This is an important prereq-
uisite to study the functional role of genes during tumorigene-
sis. In addition, the observed effects of tumor growth
inhibition in vivo as a result of Plk1 knockdown further sup-
port the use of RNAi-based strategies for cancer therapy (52)
and highlight the role of Plk1 as a potent target to prevent
tumorigenesis (53,54). Although the application of siRNA/
Plk1 was assayed in murine studies (55) and small molecular
weight inhibitors targeting Plk1 are currently being tested in
clinical settings for their potential to ﬁght neoplastic progres-
sion in humans (56), our study provides additional insight
into the function of RNAi-based genomic elements, which
is an important prerequisite for the generation of transgenic
mouse models resting upon RNAi.
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